公开(公告)号：US10525106B2

公开(公告)日：2020-01-07

申请号：US16282199

申请日：2019-02-21

Applicant: Regeneron Pharmaceuticals, Inc. ,  University Health Network

Inventor： Lisa Arleen Purcell ,  Sarah J. Higgins ,  Kevin C. Kain

IPC: A61K31/365 ,  A61K38/18 ,  A61K38/16 ,  A61K38/17 ,  A61K39/395 ,  C07K16/22 ,  A61K45/06 ,  A61K31/357 ,  A61K31/49 ,  C07K14/515 ,  A61K39/00

Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

公开(公告)号：USRE47731E1

公开(公告)日：2019-11-19

申请号：US15912884

申请日：2018-03-06

Applicant: University Health Network

Inventor： Peter Brent Sampson ,  Yong Liu ,  Sze-Wan Li ,  Bryan T. Forrest ,  Heinz W. Pauls ,  Louise G. Edwards ,  Miklos Feher ,  Narendra Kumar B. Patel

IPC: A61K31/551 ,  A61K31/4427 ,  A61K31/416 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/553 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10 ,  A61K31/437 ,  A61K45/06 ,  C07D401/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：US10475537B2

公开(公告)日：2019-11-12

申请号：US14898060

申请日：2014-06-12

Applicant: University Health Network

Inventor： Thomas G. Purdie ,  Christopher James McIntosh ,  Igor Svistoun

IPC: G06F19/00 ,  G16H50/20 ,  A61N5/10 ,  G16H40/20 ,  G16H10/60 ,  G16H50/70

Abstract: Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used.

公开(公告)号：US10472353B2

公开(公告)日：2019-11-12

申请号：US16389119

申请日：2019-04-19

Applicant: University Health Network

Inventor： Peter Brent Sampson ,  Miklos Feher ,  Heinz W. Pauls

IPC: C07D413/14

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.

公开(公告)号：US20190336537A1

公开(公告)日：2019-11-07

申请号：US16466278

申请日：2017-12-04

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Gordon Keller ,  Stephanie Protze ,  Jee Hoon Lee

IPC: A61K35/28 ,  A61K35/34 ,  G01N33/50 ,  G01N33/68 ,  A61P9/04 ,  C12N5/077

Abstract: Methods are disclosed for producing populations of cardiomyocytes from pluripotent stem cells. Populations may be enriched for either atrial or ventricular cardiomyocytes and the resulting ventricular population may be essentially free of pacemaker cells. The method includes incubating pluripotent stem cells in a suitable medium with a BMP component, and an activin component, the amounts of activin may be varied to enrich for either atrial or ventricular cardiomyocytes. The enriched populations, as well as methods of using the same to treat patients in need of cardiac repair are disclosed.

公开(公告)号：US10441668B2

公开(公告)日：2019-10-15

申请号：US15533799

申请日：2015-12-08

Applicant: University Health Network

Inventor： Arash Zarrine-Afsar ,  David Anthony Jaffray

IPC: A61K49/10 ,  A61K49/00 ,  A61K49/04 ,  G01N27/00 ,  G01N33/483 ,  G01N33/58 ,  H01J49/00 ,  H01J49/10

Abstract: Various embodiments are described herein for a system and a method for identifying a region of interest in tissue using mass spectrometry. An agent administration component can be provided to administer an exogenous agent to the tissue. A sampling unit can also be provided to acquire a sample from the tissue. The sample can then be provided to a high sensitivity analysis platform, such as a mass analyzer, to analyze the sample and determine a distribution of the exogenous agent or a by-product of the exogenous agent within the tissue based on the analysis. The analysis platform can then identify the region of interest based on the distribution of the exogenous agent or the distribution of the by-product.

公开(公告)号：US20190250165A1

公开(公告)日：2019-08-15

申请号：US16245328

申请日：2019-01-11

Applicant: The Governing Council of the University of Toronto ,  University Health Network

Inventor： Mark Nitz ,  Landon J. Edgar ,  Bradly G. Wouters ,  David Hedley ,  Lisa M. Willis ,  Matthew A. Lumba ,  Hanuel Park ,  Ravi N. Vellanki

IPC: G01N33/58 ,  G01N33/569 ,  C07D345/00 ,  C07D421/06 ,  C07H15/04

CPC classification number: G01N33/58 ,  C07D345/00 ,  C07D421/06 ,  C07H15/04 ,  G01N33/569 ,  G01N2458/15 ,  G01N2560/00

Abstract: A compound of formula (I): as described herein and methods and uses thereof as for mass tagging a biosensor or biologically active material.

公开(公告)号：US20190248775A1

公开(公告)日：2019-08-15

申请号：US16389119

申请日：2019-04-19

Applicant: University Health Network

Inventor： Peter Brent Sampson ,  Miklos Feher ,  Heinz W. Pauls

IPC: C07D413/14

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.

公开(公告)号：US10358436B2

公开(公告)日：2019-07-23

申请号：US15902143

申请日：2018-02-22

Applicant: University Health Network

Inventor： Peter Brent Sampson ,  Yong Liu ,  Sze-Wan Li ,  Bryan T. Forrest ,  Heinz W. Pauls ,  Louise G. Edwards ,  Miklos Feher ,  Narendra Kumar B. Patel ,  Radoslaw Laufer

IPC: A61K31/5377 ,  C07D403/10 ,  C07D403/04 ,  C07D413/14 ,  C07D231/56 ,  C07D403/14 ,  A61K45/06

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：US10350237B2

公开(公告)日：2019-07-16

申请号：US14765992

申请日：2014-02-04

Applicant: University Health Network

Inventor： Ren-Ke Li

IPC: A61K9/10 ,  A61K31/787 ,  A61K31/785 ,  A61L27/26 ,  A61L27/50 ,  A61L31/04 ,  A61L31/14 ,  C08G61/12 ,  A61K47/61 ,  A61K47/64 ,  A61K47/69 ,  A61K9/00 ,  A61K47/36

Abstract: A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.